As a physician struggling with his weight, Jay S. Feldstein shares his personal journey with the obesity drug Ozempic in a reflective piece. He highlights the complexities of obesity, which is influenced by genetic, psychosocial, environmental, and behavioral factors along with the basic physics of calories in vs. calories out. Even with his knowledge of culinary medicine, Feldstein found himself in a familiar cycle of weight gain and loss over nearly 30 years. His experience with Ozempic resulted in significant weight loss, improved A1C levels, and resolution of sleep apnea, but also raised questions about long-term reliance on the drug.
Feldstein’s attempt to wean off Ozempic led to the rapid return of his appetite and weight gain, underscoring the challenges faced by many in maintaining weight loss. He discusses the prevalence of obesity in the U.S. and the struggle faced by individuals to sustain weight loss despite following traditional advice such as exercise and portion control. The common pattern of initial weight loss followed by regain is described by researchers as “near-ubiquitous” and suggests the need for more effective long-term solutions.
The author acknowledges the intricate interplay of personal willpower and external factors such as evolutionary traits and the food industry in shaping obesity. He grapples with the decision to resume Ozempic due to the significant financial and health investments made during his initial weight loss journey. Reflecting on the cost-benefit analysis of continuing drug therapy for obesity, Feldstein draws parallels with other chronic diseases that require ongoing medication for management.
Feldstein urges a broader perspective on the treatment of obesity as a chronic and deadly disease, emphasizing the importance of effective interventions like Ozempic. While recognizing the individual challenges and tradeoffs involved in using such drugs, he advocates for a focus on the broader implications for millions of patients. He calls for a nuanced discussion on the cost, supply, and equitable access to obesity medications, highlighting the potential impact on the healthcare system and wider economy.
The article concludes with the author’s plea to consider the broader societal implications of obesity treatment and the potential transformation of healthcare systems and economies. Feldstein’s personal experience with Ozempic serves as both a testimonial and a cautionary tale, prompting reflection on the complexities of obesity management and the need for comprehensive solutions. Overall, the piece underscores the need for continued dialogue and research on obesity treatments to address the significant public health challenge.
